iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/23152524/
Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb;87(3):1544-53.
doi: 10.1128/JVI.02294-12. Epub 2012 Nov 14.

Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment

Doug J Bartels  1 , James C Sullivan, Eileen Z Zhang, Ann M Tigges, Jennifer L Dorrian, Sandra De Meyer, Darin Takemoto, Elizabeth Dondero, Ann D Kwong, Gaston Picchio, Tara L Kieffer
Affiliations

Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment

Doug J Bartels et al. J Virol. 2013 Feb.

Abstract

The prevalence of naturally occurring hepatitis C virus (HCV) variants that are less sensitive to direct-acting antiviral (DAA) inhibitors has not been fully characterized. We used population sequence analysis to assess the frequency of such variants in plasma samples from 3,447 DAA-naive patients with genotype 1 HCV. In general, HCV variants with lower-level resistance (3- to 25-fold increased 50% inhibitor concentration [IC(50)]) to telaprevir were observed as the dominant species in 0 to 3% of patients, depending on the specific variant, whereas higher-level resistant variants (>25-fold-increased IC(50)) were not observed. Specific variants resistant to NS5A inhibitors were predominant in up to 6% of patients. Most variants resistant to nucleo(s/t)ide active-site NS5B polymerase inhibitors were not observed, whereas variants resistant to non-nucleoside allosteric inhibitors were observed in up to 18% of patients. The presence of DAA-resistant variants in NS5A, NS5B, or NS3 (including telaprevir-resistant variants), in baseline samples of treatment-naive patients receiving a telaprevir-based regimen in phase 3 studies did not affect the sustained viral response (SVR). Treatment-naive patients with viral populations containing the telaprevir-resistant variants NS3 V36M, T54S, or R155K at baseline achieved a 74% SVR rate, whereas patients with no resistant variants detected prior to treatment achieved a 76% SVR rate. The effect of specific resistant variant frequency on response to various DAA treatments in different patient populations, including interferon nonresponders, should be further studied.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Comparison of early response to T/PR (telaprevir, peginterferon, and ribavirin) in treatment-naive patients with or without predominant telaprevir-resistant variants prior to treatment. The y axis displays the mean HCV RNA decline from baseline through the first 4 weeks of treatment. The results obtained for treatment-naive patients with the lower-level telaprevir-resistant variants V36M (green; n = 6), T54S (blue; n = 50), or R155K (red; n = 10) prior to treatment with telaprevir, peginterferon, and ribavirin (including patients enrolled to receive 8 weeks of telaprevir [19]) are indicated. For comparison, the median HCV RNA decline for patients who received a regimen of 12 weeks of telaprevir with response-guided peginterferon and ribavirin (black) in the phase 3 treatment, i.e., the Naive ADVANCE Study (19), is also shown. Results for all patients in the ADVANCE study receiving peginterferon and ribavirin (gray) and the subpopulation of patients receiving peginterferon and ribavirin that had undetectable HCV RNA at week 4 (RVR) are indicated by a dashed gray line.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kieffer TL, Kwong AD, Picchio GR. 2009. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J. Antimicrob. Chemother. 10:10 - PubMed
    1. Sarrazin C, Zeuzem S. 2009. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138:447–462 - PubMed
    1. Ray SC, Thomas DL. 2009. Bennett's principles and practice of infectious diseases, 7th ed, vol 1 Churchill Livingstone, New York, NY
    1. Zeuzem S. 1999. Clinical implications of hepatitis C viral kinetics. J. Hepatol 31(Suppl 1):61–64 - PubMed
    1. Adiwijaya BS, Herrmann E, Hare B, Kieffer T, Lin C, Kwong AD, Garg V, Randle JC, Sarrazin C, Zeuzem S, Caron PR. 2010. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput. Biol. 6:e1000745 doi:10.1371/journal.pcbi.1000745 - DOI - PMC - PubMed

Publication types

Associated data

LinkOut - more resources